GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » 12-1 Month Momentum %

Cannara Biotech (TSXV:LOVE) 12-1 Month Momentum % : -20.83% (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-06-09), Cannara Biotech's 12-1 Month Momentum % is -20.83%.

The industry rank for Cannara Biotech's 12-1 Month Momentum % or its related term are showing as below:

TSXV:LOVE's 12-1 Month Momentum % is ranked worse than
68.68% of 1111 companies
in the Drug Manufacturers industry
Industry Median: -4.75 vs TSXV:LOVE: -20.83

Competitive Comparison of Cannara Biotech's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's 12-1 Month Momentum % falls into.



Cannara Biotech  (TSXV:LOVE) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannara Biotech  (TSXV:LOVE) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Cannara Biotech 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech (TSXV:LOVE) Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director

Cannara Biotech (TSXV:LOVE) Headlines

From GuruFocus

LOVESAC INVESTOR DEADLINE APPROACHING

By PRNewswire 01-04-2024